Unichem Laboratories’ Ghaziabad facility has received an establishment inspection report (EIR) from the US health regulator.
The inspection was conducted by the United States Food and Drug Administration (USFDA) in April 2018, Unichem Laboratories said in a filing to the BSE today.
“Unichem’s formulation manufacturing facility at Ghaziabad has received an EIR from the USFDA indicating closure of inspection,” it added.
Shares of Unichem Laboratories were trading at Rs 234.60 per scrip on BSE, down 2.41 per cent from their previous close.